Radiation Oncology Basics Practice Questions

Q: Which of the following tumors is considered radioresistant?

Osteosarcoma. ### Explanation The radiosensitivity of a tumor is primarily determined by its cell of origin, growth fraction, and inherent DNA repair mechanisms. **Why Osteosarcoma is the Correct Answer:** **Osteosarcoma** is a primary bone-forming malignancy characterized by the production of osteoid. It is classically considered **radioresistant**. This resistance is attributed to the tumor's slow doubling time in certain areas, its ability to repair sublethal radiation damage effectively, and the dense, mineralized matrix it produces. Because it does not respond predictably to standard radiotherapy doses, the primary treatment modality remains surgical resection with neoadjuvant and adjuvant chemotherapy. **Analysis of Incorrect Options:** * **A. Ewing’s Sarcoma:** Unlike Osteosarcoma, Ewing’s is a small round blue cell tumor. These tumors typically have a high growth fraction and are highly **radiosensitive**. Radiotherapy is a standard component of management, especially for local control. * **B. Retinoblastoma:** This is a highly **radiosensitive** embryonal tumor. While laser and cryotherapy are used for small lesions, radiotherapy (external beam or brachytherapy) is an effective treatment for larger tumors. * **C. Neuroblastoma:** Another member of the small round blue cell tumor family, it is generally **radiosensitive**. Radiation is frequently used in high-risk cases to treat the primary site or metastatic deposits. **NEET-PG High-Yield Pearls:** * **Most Radiosensitive Tumors:** Seminoma, Dysgerminoma, Lymphoma, and Small round blue cell tumors (Ewing’s, Wilms’, Neuroblastoma). * **Most Radioresistant Tumors:** Osteosarcoma, Chondrosarcoma, Malignant Melanoma, and Renal Cell Carcinoma (RCC). * **Bergonie-Tribondeau Law:** Cells are more radiosensitive if they have a high mitotic rate, a long mitotic future, and are undifferentiated.

Q: Point A and Point B in Manchester localization are used in the radiotherapy treatment of which cancer?

Cervix. **Explanation:** The **Manchester System** is a classic dosimetry system used in **Brachytherapy** for the treatment of **Carcinoma Cervix**. It utilizes specific anatomical reference points to ensure adequate dosage to the tumor while sparing surrounding critical structures. * **Point A:** Located 2 cm superior to the external cervical os and 2 cm lateral to the midline (uterine canal). It represents the location where the uterine artery crosses the ureter. It is the primary point for dose prescription, as it corresponds to the paracervical triangle. * **Point B:** Located 3 cm lateral to Point A (5 cm from the midline). It represents the pelvic side wall and the location of the obturator lymph nodes. It is used to assess the dose to the lateral pelvic structures. **Why other options are incorrect:** * **Kidney:** Radiotherapy for renal tumors (like Wilms tumor) typically involves External Beam Radiation Therapy (EBRT), not intracavitary brachytherapy using the Manchester system. * **Uterus:** While endometrial cancer may use brachytherapy, the Manchester system is specific to the anatomy of the cervix and the paracervical tissues. * **Vagina:** Primary vaginal cancers use different dosimetry systems often based on the depth of the lesion or the surface of the vaginal cylinder, rather than Points A and B. **High-Yield Clinical Pearls for NEET-PG:** * **Point A** is the point of **prescription**; **Point B** is the point of **monitoring** (pelvic wall dose). * The dose at Point B is typically **1/3rd to 1/4th** of the dose at Point A. * Modern radiotherapy is shifting from Point A-based planning to **Image-Guided Brachytherapy (IGBT)** using MRI to define the High-Risk Clinical Target Volume (HR-CTV).

Q: What is the long-term effect of craniospinal irradiation for medulloblastoma?

Neurocognitive effects. **Explanation:** Craniospinal irradiation (CSI) is a standard treatment for medulloblastoma, but the developing brain is highly sensitive to radiation. **Neurocognitive decline** is the most significant and pervasive long-term complication, particularly in younger children. The underlying mechanism involves radiation-induced damage to the white matter, hippocampal progenitor cells, and microvasculature, leading to deficits in processing speed, executive function, and IQ over time. **Analysis of Options:** * **C. Neurocognitive effects (Correct):** This is the most common and debilitating long-term sequela. The decline is progressive and inversely proportional to the age at the time of treatment (younger children suffer more severe deficits). * **A. Secondary malignancy:** While CSI increases the risk of secondary tumors (like meningiomas or sarcomas) later in life, the incidence is lower compared to the near-universal occurrence of some degree of cognitive impairment. * **B. Neuroendocrine abnormalities:** Growth hormone deficiency and hypothyroidism are common due to hypothalamic-pituitary axis irradiation; however, these are often manageable with replacement therapy, whereas neurocognitive damage is largely irreversible. * **D. Hearing loss:** This is primarily a side effect of **Cisplatin** chemotherapy (ototoxicity) rather than the radiation itself, although radiation can exacerbate it. **High-Yield Clinical Pearls for NEET-PG:** * **Age Factor:** To minimize neurocognitive damage, radiation is generally avoided or delayed in children under **3 years** of age. * **Proton Beam Therapy:** This is increasingly preferred over conventional photon radiation for CSI because it reduces the "exit dose," sparing the heart, lungs, and bowel from unnecessary radiation. * **Medulloblastoma Origin:** It arises from the **vermis** in children (midline) and the **cerebellar hemispheres** in adults.

Q: Which of the following radioisotopes is considered obsolete in modern clinical practice?

Radium-226 (Ra226). **Explanation:** **Radium-226 (Ra-226)** is considered obsolete in modern clinical practice primarily due to significant safety concerns. Discovered by Marie Curie, it was the first isotope used for brachytherapy. However, it has been replaced because: 1. **Radon Gas Leakage:** Its decay product is Radon-222, a gaseous alpha-emitter. If the source capsule is breached, it poses a severe inhalation hazard. 2. **Long Half-life:** With a half-life of **1,600 years**, any accidental loss or contamination results in a permanent environmental hazard. 3. **High Energy:** It emits a wide spectrum of high-energy gamma rays, making radiation shielding difficult for staff. **Analysis of Incorrect Options:** * **Cobalt-60 (Co-60):** Still widely used in external beam radiotherapy (Telecobalt units), especially in developing countries, and in Gamma Knife radiosurgery. * **Iridium-192 (Ir-192):** The current **"gold standard"** for High-Dose-Rate (HDR) brachytherapy due to its high specific activity and smaller source size. * **Cesium-137 (Cs-137):** Though being phased out in some regions, it is still used for Low-Dose-Rate (LDR) brachytherapy (e.g., cervical cancer) as a safer alternative to Radium. **High-Yield Clinical Pearls for NEET-PG:** * **Historical Context:** Radium was the original "standard" for brachytherapy (the term "mg-hours" originates from Radium). * **Replacement:** **Cesium-137** is the direct clinical substitute for Radium-226 in LDR applications. * **Safety:** Modern brachytherapy uses "afterloading" techniques to minimize staff exposure, a practice that was difficult with early Radium needles.

Q: Management of osteoradionecrosis would require all of the following EXCEPT?

Non removal of sequestrum. **Explanation:** Osteoradionecrosis (ORN) is a serious complication of radiation therapy, most commonly affecting the mandible. It is characterized by non-healing, exposed bone in a previously irradiated area (usually >60 Gy) that fails to heal for over 3–6 months. **Why "Non-removal of sequestrum" is the correct answer:** The management of ORN follows a surgical-medical approach. A **sequestrum** (a piece of dead bone that has become separated during the process of necrosis) acts as a nidus for persistent infection and prevents healing. Therefore, **surgical debridement or sequestrectomy** (removal of the sequestrum) is a fundamental step in management to allow healthy, vascularized tissue to recover. "Non-removal" is contraindicated. **Analysis of other options:** * **Antibiotic coverage:** Essential to manage secondary infections (osteomyelitis) that frequently complicate necrotic bone. * **Hyperbaric oxygen (HBO):** Used to reverse the "3-H" effects of radiation (Hypocellularity, Hypovascularity, and Hypoxia) by stimulating angiogenesis and collagen synthesis. * **Fluoride application:** Preventive dental care is vital. Since radiation destroys salivary glands (leading to xerostomia), patients are at high risk for radiation caries. Daily fluoride application helps maintain dental integrity and prevents the need for extractions, which could trigger ORN. **NEET-PG Clinical Pearls:** * **Most common site:** Mandible (due to lower vascularity compared to the maxilla). * **Threshold dose:** Risk increases significantly with doses >60 Gy. * **Marx Protocol:** Often used for HBO therapy in ORN (30 sessions before surgery, 10 sessions after). * **PENTOCLO Protocol:** A modern medical management involving Pentoxifylline, Tocopherol (Vitamin E), and Clodronate.

Q: A patient who underwent dental extraction prior to radiotherapy needs:

Adequate time for healing. **Explanation:** The correct answer is **B. Adequate time for healing.** **Underlying Medical Concept:** Radiotherapy to the head and neck region significantly impairs the vascularity of the mandible and maxilla by causing endarteritis obliterans. If radiation is started immediately after a dental extraction, the socket fails to heal due to reduced blood supply and impaired osteoblastic activity. This creates a pathway for infection to reach the hypoxic bone, leading to **Osteoradionecrosis (ORN)**—a severe, painful, and debilitating complication characterized by non-healing bone necrosis. To prevent this, a healing period of typically **10 to 14 days** (or until complete mucosalization of the socket) is mandatory before initiating radiotherapy. **Analysis of Incorrect Options:** * **Option A & D:** Starting treatment with "no time" or only "one day" of healing is contraindicated. The surgical site remains an open wound; radiation will arrest the inflammatory healing phase, leading to wound dehiscence and subsequent ORN. * **Option C:** Radiotherapy is not contraindicated. In fact, pre-radiation dental clearance (extracting teeth with poor prognosis) is a standard prophylactic measure to avoid the need for extractions *after* therapy, which carries an even higher risk of ORN. **High-Yield Clinical Pearls for NEET-PG:** * **Osteoradionecrosis (ORN):** Most commonly affects the **mandible** (due to its lower vascularity compared to the maxilla). * **The "Golden Period":** If extractions are necessary post-radiation, they should ideally be avoided. If mandatory, hyperbaric oxygen (HBO) therapy is often used to improve tissue oxygenation. * **Radiation Dose:** The risk of ORN increases significantly with doses exceeding **60 Gy**. * **Prophylaxis:** Patients should maintain meticulous oral hygiene and use topical fluoride to prevent radiation-induced dental caries.

Q: What is the maximum recommended external beam radiation therapy dose for carcinoma of the cervix?

50 Gy. **Explanation:** In the management of carcinoma cervix, the standard treatment approach involves a combination of **External Beam Radiation Therapy (EBRT)** and **Brachytherapy**. The primary goal of EBRT is to sterilize the pelvic lymph nodes and reduce the bulk of the central tumor. The maximum recommended dose for EBRT is typically **45–50 Gy** (delivered in fractions of 1.8–2.0 Gy over 5 weeks). Exceeding this dose with external beams significantly increases the risk of chronic toxicity to surrounding "organs at risk" (OARs), such as the small bowel, bladder, and rectum, which have lower tolerance limits. To achieve the high curative doses required for the central cervix (80–90 Gy), brachytherapy is used to provide a concentrated dose while sparing these adjacent structures. **Analysis of Options:** * **Option C (50 Gy):** Correct. This is the upper limit for whole-pelvis EBRT to ensure regional control without causing unacceptable bowel or bladder morbidity. * **Options A & B (80 Gy & 70 Gy):** These represent the *total* cumulative dose (EBRT + Brachytherapy) required for tumor eradication. Delivering this dose via EBRT alone would cause severe radiation enteritis and fistulas. * **Option D (35 Gy):** This dose is sub-therapeutic for definitive management and is insufficient to control pelvic lymph node micrometastases. **High-Yield Clinical Pearls for NEET-PG:** * **Point A:** Located 2 cm superior to the external os and 2 cm lateral to the uterine canal. It represents where the uterine artery crosses the ureter. The target dose for Point A is usually **80–85 Gy**. * **Point B:** Located 5 cm lateral to the midline; it represents the pelvic side wall and lymph nodes. * **Standard Protocol:** EBRT (45–50 Gy) with concurrent **Cisplatin** (radiosensitizer), followed by Intracavitary Brachytherapy (ICBT).

Q: Which of the following tumors is associated with the abscopal effect?

Chronic lymphocytic leukemia. **Explanation:** The **Abscopal Effect** is a rare phenomenon in radiation oncology where localized radiation treatment to a primary tumor site results in the regression of distant, non-irradiated metastatic lesions. This effect is mediated by the **immune system**; radiation induces immunogenic cell death, releasing tumor-associated antigens that prime T-cells to mount a systemic anti-tumor response. **Why Chronic Lymphocytic Leukemia (CLL) is correct:** CLL is the classic example among the options provided. Historically, the abscopal effect was frequently documented in patients with CLL or low-grade lymphomas who received splenic irradiation, leading to a significant reduction in distant lymphadenopathy and an improvement in peripheral blood counts. Because CLL is a malignancy of mature B-cells that circulate through the lymphoid system, it is particularly susceptible to this immune-mediated systemic "bypass" effect. **Why other options are incorrect:** * **CML, ALL, and AML:** While theoretically possible, the abscopal effect is rarely reported in acute leukemias or CML. These are aggressive, rapidly proliferating myeloid or immature lymphoid malignancies where the primary treatment is systemic chemotherapy or targeted therapy (like TKIs in CML), rather than localized radiotherapy. The immune environment in acute leukemias is often too suppressive or the disease progression too rapid for the abscopal effect to manifest clinically. **NEET-PG High-Yield Pearls:** * **Mechanism:** Radiation + Immune System = Systemic Response. * **Commonly associated tumors:** Melanoma, Renal Cell Carcinoma (RCC), and Lymphomas (including CLL). * **Modern Context:** The interest in the abscopal effect has surged recently due to the use of **Checkpoint Inhibitors** (e.g., PD-1 inhibitors), which synergize with radiotherapy to enhance this systemic response.

Question 1

Which of the following tumors is considered radioresistant?

Accepted Answer

Osteosarcoma

Answer

Ewing's sarcoma

Answer

Retinoblastoma

Answer

Neuroblastoma

Question 2

Point A and Point B in Manchester localization are used in the radiotherapy treatment of which cancer?

Accepted Answer

Cervix

Answer

Kidney

Answer

Uterus

Answer

Vagina

Question 3

What is the long-term effect of craniospinal irradiation for medulloblastoma?

Accepted Answer

Neurocognitive effects

Answer

Secondary malignancy

Answer

Neuroendocrine abnormalities

Answer

Hearing loss

Question 4

Which of the following radioisotopes is considered obsolete in modern clinical practice?

Accepted Answer

Radium-226 (Ra226)

Answer

Cobalt-60 (Co60)

Answer

Iridium-192 (Ir192)

Answer

Cesium-137 (Cs137)

Question 5

Which is the most radio-resistant tumor?

Accepted Answer

Osteosarcoma

Answer

Malignant fibrous histiocytoma

Answer

Ewing's sarcoma

Answer

Multiple myeloma

Question 6

Radiation caries develops in approximately what time frame?

Accepted Answer

3 months

Answer

3 weeks

Answer

3 days

Answer

3 years

Question 7

Management of osteoradionecrosis would require all of the following EXCEPT?

Accepted Answer

Non removal of sequestrum

Answer

Antibiotic coverage

Answer

Hyperbaric oxygen

Answer

Fluoride application

Question 8

A patient who underwent dental extraction prior to radiotherapy needs:

Accepted Answer

Adequate time for healing

Answer

No time for healing

Answer

Radiotherapy is not advised

Answer

To wait for one day to start radiotherapy

Question 9

What is the maximum recommended external beam radiation therapy dose for carcinoma of the cervix?

Accepted Answer

50 Gy

Answer

80 Gy

Answer

70 Gy

Answer

35 Gy

Question 10

Which of the following tumors is associated with the abscopal effect?

Accepted Answer

Chronic lymphocytic leukemia

Answer

Chronic myeloid leukemia

Answer

Acute lymphoblastic leukemia

Answer

Acute myelogenous leukemia

Radiation Oncology Basics — MCQs

Radiation Oncology Basics — MCQs

On this page

Practice by Chapter

Want unlimited practice?